Testing GLK-221 Eye Drops for Keratoconus
Part of Eyes & vision clinical trials.
This study tests an eye drop called GLK-221 for people with keratoconus, a condition where the clear front of the eye bulges. The goal is to see if the drops can safely help improve the condition compared to a placebo (an inactive solution).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old.
- You must have keratoconus in at least one eye.
- If you are a woman, you cannot be pregnant, breastfeeding, or planning a pregnancy during the study.
- You cannot be currently enrolled in or have been in another experimental drug or device trial within the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eyedrop (TN-001) for people with keratoconus that is getting worse. The drops are applied twice a day to try to stop the cornea from thinning and bulging further.
This study follows people with or at risk for keratoonus, a condition where the cornea thins and bulges. It aims to improve early detection and understand how the disease progresses.
This study looks at how people with keratoconus decide to take part in clinical research. It's for people who haven't had any treatment for keratoconus yet, and it may help improve future research studies for this condition.
This study tests a procedure called Xenia corneal lenticule in people with severe keratoconus or severe post-LASIK corneal thinning who want to avoid a corneal transplant. It aims to improve vision while checking safety and how well the new procedure works over time.
This trial compares two ways to manage inflammation after corneal crosslinking for keratoconus: a tiny steroid insert placed in the tear duct versus standard steroid eye drops. It aims to see which option is easier and works just as well.
This study looks at what leads to keratoconus and how it progresses over time. It may help doctors better predict worsening vision and plan earlier care.
Hear when a new Keratoconus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.